Pharmacodynamic and pharmacokinetic drug interaction of gliclazide and lacidipine in animal models

Indian Journal of Pharmaceutical Education and Research

Volumn 42, Issue 3, 2008, Pages 277-282

  Eswar Kumar, K ^a   Ramesh, A ^a   Satyanarayana, S ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Drug interactions; Gliclazide; Lacidipine; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALLOXAN; GLICLAZIDE; GLUCOSE; LACIDIPINE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; DISTRIBUTION VOLUME; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NONHUMAN; PHARMACODYNAMICS; RABBIT; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN PUNCTURE;

EID: 74549152613     PISSN: 00195464     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Morrish NJ, Wang SI, Stevens LK, Fuller JH, Keen H and the WHO Multinational Study Group. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetalogia 2001; 44(2): S14-S21.
2. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular complications in type-2 diabetes (UKPDS, 38). BMJ 1998; 317: 703-713.
3. Schernthaner G: Gliclazide modified release: A critical review of pharmacodynamic, metabolic and vasoprotective effects. Metabolism 2003; Aug 52 (8 suppl 1): 29-34.
4. Song DK, Ashcroft FM: Glimepiride block of cloned cell, cardiac and smooth muscle K+ATP channels. Br J Pharmacol. 2001; 133 (1): 193-99.
5. Gribble FM, Tucker SJ, Seino S, Ashcroft FM: Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998; 47 (9): 1412-18.
6. Jennings PE, Belch JJF: Free radical scavenging activity of sulphonylureas: a clinical assessment of the effectiveness of gliclazide. Ter Arkh. 2001; 73(4): 27-31.
7. Brien RC, Luo M, Balazs N, Mercuri J: In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000; Jul-Aug 14(4): 201-6.
8. Homes B, Heel RC, Brogden RN, Speight TM, Avery GS: Gliclazide - A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 1984; Apr 27(4): 301-27.
9. Harrower AD: Efficacy of gliclazide in comparision with other sulphonylureas in the treatment of NIDDM. Diabetes Res Clin Pract 1991; 14 (Suppl 2): S65-7.
10. Harrower AD: Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety 2000; Apr 22(4); 313-20.
11. Ziegler O, Drouin P: Hemobiological properties of gliclazide. J diabetes complications 1994; Oct-Dec; 8(4): 235-9.
12. Palmer KJ and Brogden RN: Gliclazide: an update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46:92-125.
13. Fava D, Cassone-Faldetta M, Laurenti O, De luca O, Ghiselli A, De Mattia G: Gliclazide improves antioxidant status and nitric oxide mediated vasodilation in type-2 diabetes. Diabet Med 2002; 19(9): 752-7.
14. Bataille D. Molecular mechanisms of insulin secretion. Diabetes Metab 2002; 28(6): 4S7-13.
15. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non carcinogenic chemogen. J Clin Pathol 1969; 22:158-61.
16. Heikkila RE: The prevention of alloxan-induced diabetes in mice by dimethyl sulfoxide. Eur J Pharmacol 1977; 44(2): 191-93.
17. K. Eswar Kumar, A. Ramesh, R. Surendra Yadav and S. Satyanarayana. Determination of gliclazide in rabbit serum by RP-HPLC. Acta Ciencia Indica 2007; 7.
18. Gribble FM, Reimann F: Differential selectivity of insulin secretogogues: mechanism, clinical implications and drug interactions. J. Diabetes complications. 2003; Mar-Apr; 17(2): 11-5.
19. Rajan AS, Aguilar-Bryan L, Nelson DA, Yaney GC, Hsu WH, Kunze DL, Boyd AE: Ion channels and insulin secretion. Diabetes Care Mar 1990; 13(3): 340-63.
20. Rang HP, Dale MM, Ritter JM. Pharmacology 2003; 5th ed. Edinburgh: Churchill Livingstone; 52-53.
21. Walters RJ. Diabetes: A Primier 2003. Available from: www.cellscience.com of diabetes.htm.
22. Leonetti G & The Northern Italian Study Group of Lacidipine in Hypertension: Comparative study of lacidipine and nifedipine SR in the treatment of hypertension: an Italian multicenter study. J Cardiovasc Pharmacol. 1991; 17(suppl 4):S31-S34.
23. Hall ST, Harding SM, Evans GL et al. Clinical pharmacology of lacidipine. J Cardiovasc Pharmacol 1991; 17(4): S9-S13.
24. Galeone F, Giuntoli F, Fiore G, Brunelleschi G, Saba P. Antihypertensive and metabolic effects of lacidipine in patients with NIDDM and/or hypertension. J Cardiovasc Pharmacol 1994; 23 Supl 5: S 105-7.
25. Spieker C, Zidek W. The impact of lacidipine, a novel dihydropyridine calcium antagonist, on carbohydrate and lipid metabolism. J Cardiovascular Pharmacol 1995; 25 suppl 3: S23-6.
26. Miyazaki H, Fijii T, Yoshida K, Arakawa S, Furukawa H. Disposition and metabolism of 3H gliclazide in rats. Eur J Drug Metab Pharmacokinet 1983; 8: 117-31.
27. Benakis A, Glasson B. Metabolic study of 14Clabelled gliclazide in normal rats and in rats with streptozotocin-induced diabetes. In Gliclazide and Treatment of Diabetes, ed. Keen H. London: Academic Press and the Royal Society of Medicine 57-69, 1980.
28. Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clin Pharmacokinet 1979; 4: 368-79.
29. Bhatnager SK, Amin MM and Al-Yusuf AR. Diabetogenic effects of nifidipine. Br Med J 1984; 289: 19.
30. Campbell DB, Lavielle R and Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract. 1991.